Find us easily
View access map
A cutting-edge research center
A center of excellence for biotechnology, the Center of Immunology Pierre Fabre (CIPF) is developing research programs in the field of cancer immunotherapy, in particular the identification of therapeutic monoclonal antibodies. Inaugurated in 1990, the CIPF acquired its reputation through groundbreaking developments in the production of recombinant proteins and bacterial biomasses. Originally developing vaccine approaches, since 2003 research activities focus on the discovery and characterization of monoclonal antibodies for use in oncology.The departments of Research and Industrial Biotechnology combine their specific know-how and expertise to identify antibodies, to specify their therapeutic properties and to produce them on a pre-industrial scale. Research undertaken at the CIPF up today has lead to the development of the first clinical antibody of the Pierre Fabre Group. Cancer immunotherapy constitutes a major area of antitumor therapy, of which the CIPF is at the cutting edge.
:: FOCUS ::
Antibodies Biotechnology Unit (UBA)
« Integration, Quality, Flexibility and Environment »…
The «Antibody Biotechnology Unit» (UBA) is the bioproduction centre of the CIPF. This facility brings additional development and production capacity for the biological molecules identified by the Research teams.
Located in France, close to the biotech heart of Geneva, the CIPF is a part of Pierre FABRE Laboratories (over 9000 people in France and overseas).